Therapy with Allogeneic SARS-CoV-2-specific T-cells for Persistent COVID-19 in Immunocompromised Patients

Publication: Clinical Infectious Diseases


We administered SARS-CoV-2 VST under emergency IND to 6 immunocompromised patients with persistent COVID-19 and characterized clinical and virologic responses: three patients had partial responses after failing other therapies but then died. Two patients completely recovered, but the role of VST in recovery was unclear due to concomitant use of other antivirals. One patient had not responded to two courses of remdesivir and experienced sustained recovery after VST. The use VST in immunocompromised patient with persistent COVID-19 requires further study.
By Ghady Haidar, Jana L Jacobs, Kailey Hughes Kramer, Asma Naqvi, Amy Heaps, Urvi Parikh, Kevin Dylan McCormick, Michele D Sobolewski, Mounzer Agha, Tatiana Bogdanovich, Vasilii Bushunow, Rafic Farah, Matthew Hensley, Yen-Michael S Hsu, Bruce Johnson, Cynthia Klamar-Blain, Jennifer Kozar, Elizabeth Lendermon, Bernard JC Macatangay, Christopher C Marino, Anastasios Raptis, Erin Salese, Fernanda P Silveira, Ann M Leen, William L Marshall, Michael Miller, Badrish Patel,Ercem Atillasoy, John W Mellors